Cargando…

Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort

Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease with a variable clinical course. Biomarkers that predict patient outcomes are needed. We leveraged data from 300 patients in the multicenter IPF-PRO Registry to determine associations between circulating proteins and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Todd, Jamie L., Neely, Megan L., Overton, Robert, Mulder, Hillary, Roman, Jesse, Lasky, Joseph A., de Andrade, Joao A., Gulati, Mridu, Huang, Howard, Leonard, Thomas B., Hesslinger, Christian, Noth, Imre, Belperio, John A., Flaherty, Kevin R., Palmer, Scott M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Idiopathic Pulmonary Fibrosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881240/ https://www.ncbi.nlm.nih.gov/pubmed/35066606 http://dx.doi.org/10.1007/s00408-021-00505-y

Ejemplares similares

Blood Cell Count Derived Inflammation Indexes in Patients with Idiopathic Pulmonary Fibrosis
por: Zinellu, Angelo, et al.
Publicado: (2020)

Progranulin and Activin A Concentrations are Elevated in Serum from Patients with Acute Exacerbations of Idiopathic Pulmonary Fibrosis
por: Xie, Tian, et al.
Publicado: (2021)

Correction to: Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort
por: Todd, Jamie L., et al.
Publicado: (2022)

Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry
por: Kim, Hyun J., et al.
Publicado: (2022)

Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
por: Todd, Jamie L., et al.
Publicado: (2019)

Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort
por: Todd, Jamie L., et al.
Publicado: (2020)

Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
por: Snyder, Laurie D, et al.
Publicado: (2020)

Acceptability of patient reported outcome measures (PROMs) in a cystic fibrosis data registry
por: Ratnayake, Irushi, et al.
Publicado: (2021)

Registry-based study in people with cystic fibrosis and an R117H variant treated with ivacaftor
por: Higgins, Mark, et al.
Publicado: (2023)

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
por: Bessonova, Leona, et al.
Publicado: (2018)

Impact of newborn screening on outcomes and social inequalities in cystic fibrosis: a UK CF registry-based study
por: Schlüter, Daniela K, et al.
Publicado: (2020)

Lung function in children with cystic fibrosis in the USA and UK: a comparative longitudinal analysis of national registry data
por: Schlüter, Daniela K, et al.
Publicado: (2022)

Emulated trial investigating effects of multiple treatments: estimating combined effects of mucoactive nebulisers in cystic fibrosis using registry data
por: Granger, Emily, et al.
Publicado: (2023)

Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry
por: Snyder, Laurie, et al.
Publicado: (2019)

Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials
por: Keogh, Ruth H, et al.
Publicado: (2022)

Development of the prediction model for hypertension in patients with idiopathic inflammatory myopathies
por: Qin, Li, et al.
Publicado: (2021)

Idiopathic inflammatory myopathies and hypertension: Possible involvement of hormonal factors
por: Armanini, Decio, et al.
Publicado: (2021)

Downregulation of epithelial sodium channel (ENaC) activity in human airway epithelia after low temperature incubation
por: Yadav, Sangya, et al.
Publicado: (2021)

Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
por: Clancy, J P, et al.
Publicado: (2013)

Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial
por: Nichols, David P, et al.
Publicado: (2022)

Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure
por: Ceelen, Daan, et al.
Publicado: (2022)

International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety
por: Quittner, Alexandra L, et al.
Publicado: (2016)

Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung
por: Tagalakis, Aristides D, et al.
Publicado: (2018)

Novel method to select meaningful outcomes for evaluation in clinical trials
por: McLeod, Charlie, et al.
Publicado: (2021)

Integrating specialist palliative care to improve care and reduce suffering: cystic fibrosis (InSPIRe:CF) – study protocol for a multicentre randomised clinical trial
por: Lowers, Jane, et al.
Publicado: (2022)

Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age
por: Byrnes, Catherine Ann, et al.
Publicado: (2013)

Increased extracellular vesicles mediate inflammatory signalling in cystic fibrosis
por: Useckaite, Zivile, et al.
Publicado: (2020)

Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis
por: Dorkin, Henry L, et al.
Publicado: (2015)

Short-term comparative study of high frequency chest wall oscillation and European airway clearance techniques in patients with cystic fibrosis
por: Osman, Leyla P, et al.
Publicado: (2009)

Eradication of Pseudomonas aeruginosa in adults with cystic fibrosis
por: Kenny, S L, et al.
Publicado: (2014)

Survival models to support shared decision-making about advance care planning for people with advanced stage cystic fibrosis
por: Hajizadeh, Negin, et al.
Publicado: (2021)

Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis
por: Knibbs, Luke D, et al.
Publicado: (2014)

Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial
por: Wildman, Martin J, et al.
Publicado: (2022)

Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial
por: Podolanczuk, Anna J., et al.
Publicado: (2022)

Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design
por: Jain, Raksha, et al.
Publicado: (2022)

Longitudinal assessment of lung clearance index to monitor disease progression in children and adults with cystic fibrosis
por: Horsley, Alex R, et al.
Publicado: (2022)

Impact of cystic fibrosis on birthweight: a population based study of children in Denmark and Wales
por: Schlüter, Daniela K, et al.
Publicado: (2019)

What effective ways of motivation, support and technologies help people with cystic fibrosis improve and sustain adherence to treatment?
por: Calthorpe, Rebecca J, et al.
Publicado: (2020)

ROCK STUDY in CF: sustained anti-inflammatory effects of lumacaftor–ivacaftor in sputum and peripheral blood samples of adult patients with cystic fibrosis—an observational study
por: Arooj, Parniya, et al.
Publicado: (2023)

Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis
por: Gray, Robert D, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3h56fpbttaudpdpg7bihv8do3t